Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Stone, John H., Merkel, Peter A., Spiera, Robert, Seo, Philip, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Turkiewicz, Anthony, Tchao, Nadia K., Webber, Lisa, Ding, Linna, Sejismundo, Lourdes P., Mieras, Kathleen, Weitzenkamp, David, Ikle, David, Seyfert-Margolis, Vicki, Mueller, Mark, Brunetta, Paul, Allen, Nancy B., Fervenza, Fernando C., Geetha, Duvuru, Keogh, Karina A., Kissin, Eugene Y., Monach, Paul A., Peikert, Tobias, Stegeman, Coen, Ytterberg, Steven R., Specks, Ulrich
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3137658/
https://ncbi.nlm.nih.gov/pubmed/20647199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0909905
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller